William Doyle is recorded as Board Member at NovoCure Ltd (NVCR) since June 3, 2026 and Chairman at NovoCure Ltd (NVCR) since January 1, 2004. The newest filing on record that lists William Doyle as Chairman at NovoCure Ltd (NVCR) is dated April 20, 2026. NovoCure Ltd reported in an 8-K filed June 5, 2026 that William Doyle was appointed director, effective June 3, 2026. NovoCure Ltd reported in an 8-K filed June 6, 2025 that William Doyle was appointed director, effective June 4, 2025. NovoCure Ltd reported in an 8-K filed June 10, 2024 that William Doyle was appointed director, effective June 5, 2024. Equibles holds 4 filed executive changes naming William Doyle; each is listed under recent activity with its source filing. The proxy statement of NovoCure Ltd reports total compensation of $15,723,701 for William Doyle in fiscal 2020, including a base salary of $772,500. Disclosed compensation is on record for 4 fiscal years. William Doyle has spoken on 13 earnings calls across 1 company, most recently for NovoCure Ltd on April 30, 2026. NovoCure Ltd is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at NovoCure Ltd includes Asaf Danziger (CEO and Board Member), David Hung (CEO and Board Member), Frank Leonard (CEO and Board Member) and 7 others.
“The Company’s shareholders elected Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Frank Leonard, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2027.”
“The Company's shareholders elected Ashley Cordova, Asaf Danziger, William Doyle, Jeryl Hilleman, David Hung, Kinyip Gabriel Leung, Martin Madden, Allyson Ocean, Timothy Scannell, Kristin Stafford and William Vernon as directors, effective immediately, with a term expiring at the annual meeting of shareholders in 2026.”
“This morning, we reported results for the first quarter of 2026, and I am pleased to say we've had a strong start to the year. Both active patients and net revenues grew at double-digit rates year over year.”
“I'll begin this morning with a brief review of our 2025 accomplishments and look ahead to 2026. Our CEO, Frank Leonard, will then discuss recent commercial updates.”
“At Novocure, our mission is to extend survival in some of the most aggressive forms of cancer. Through our early years, our efforts focused mostly on the treatment of patients with glioblastoma.”
“At Novocure, our mission is to extend survival for patients diagnosed with some of the most aggressive forms of cancer through the development of Tumor Treating Fields therapy.”
“At NovoCure, our mission is to extend survival in some of the most aggressive forms of cancer through the development and commercialization of Tumor Treating Fields.”
